AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

AbbVie’s stock faced a chilly reception on May 6, plunging 4.55% and ending the day at $187.15. Despite strong fundamentals ...

AbbVie stands to benefit from a policy change eliminating the “pill penalty” in Medicare’s drug price negotiations, offering ...

After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.57%, which has investors questioning if this is right time ...

Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $300.66 today based on a ...

Shares of AbbVie (ABBV) have gained more than 12% in the past week. But now they are overbought and may reverse.

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

When Roy Bradley was told he had cancer in his lungs and liver, his first thought was he couldn't face chemotherapy and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

If Trump’s proposed tariffs are giving you worry lines, buckle up: how you treat them might be hit next. Everything from ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.